Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Neonatal fc receptor blockers

8 evidence topics · 5 sources

Subcutaneous efgartigimod randomized withdrawal trial: registry results for stage B time-to-event and disability outcomes
Stage B outcomeEfgartigimod PH20 SCPlacebo PH20 SC
Median time to first adjusted INCAT deterioration, days (95% CI)“NA[1] (NA to NA)”“140.0[2] (75.0 to NA)”
Median time to CIDP disease progression, days (95% CI)“NA[1] (247.0 to NA)”“85 (50.0 to 253.0)”
Mean (SD) change in adjusted INCAT score from stage B baseline“0.1(1.08)”“0.9(1.98)”
Subcutaneous efgartigimod randomized withdrawal trial: registry all-cause mortality and serious adverse events
EventStage A efgartigimod PH20 SCStage B efgartigimod PH20 SCStage B placebo PH20 SC
All-cause mortality, affected/at risk (%)“2/322 (0.62%)”“0/111 (0.00%)”“1/110 (0.91%)”
Serious adverse events, affected/at risk (%)“21/322 (6.52%)”“6/111 (5.41%)”“6/110 (5.45%)”